The merger with Scipher is the dominant catalyst. Monitor for SEC review of the S-4, shareholder vote, and closing expected by year-end 2026. The standalone cash position is insufficient beyond Q1 2027, making deal completion critical. Post-merger, the key catalyst is the Phase 2 RA trial initiation in H1 2027 and data in H1 2028. The CVRs provide optionality on nebokitug milestones but are not tradeable.
Drug in focus
CMMB drug pipeline →nebokitug
◆ Mixed Named in this 6-K- Impact
- Phase
- Phase 2 (complete); preparing Phase 3
- Time to market
- At least 4-6 years; Phase 3 PSC trial not yet initiated, and even if successful, filing and approval would follow several years later. The new RA program is even earlier-stage.
- Next catalyst
- None dated
What to watchThe just-announced merger with Scipher Medicine (all-stock, closing Q4 2026) reshapes the investment thesis: pre-merger Chemomab holders get ~32% of the combined entity plus CVRs tied to nebokitug milestones, while the new company will run an AI-guided Phase 2 RA trial. Watch for Phase 3 PSC trial financing clarity post-merger and the merger close vote. The stock already ran ~80% into the deal, much of the near-term re-rating may be priced in.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 19 $2.09entry
- T+1 · 3mo ago −0.96%α −0.12% · $2.07
- T+5 · 3mo ago +23.92%α +24.31% · $2.59
- T+20 · 2mo ago +33.97%α +35.92% · $2.80
- T+60 · 5d ago −33.01%α −31.46% · $1.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Chemomab reported Q2 2026 financial results and provided a corporate update centered on the proposed all-stock merger with Scipher Medicine. The company had $6.7M in cash as of June 30, 2026, with a net loss of $2.2M for the quarter. The merger, which values the combined company at $150M pre-money, would give Chemomab shareholders ~32% ownership and CVRs tied to nebokitug milestones, with the combined entity trading under 'SCIP'. The filing also includes a going-concern warning, noting cash runway only through Q1 2027 absent the merger closing, and the company has no approved products or revenue.
Key Facts
- Cash, cash equivalents and short-term bank deposits were $6.7M as of June 30, 2026, down from $8.0M as of March 31, 2026.
- Net loss for Q2 2026 was $2.2M, compared to $2.1M in Q2 2025.
- R&D expenses were $1.1M in Q2 2026 vs $1.3M in Q2 2025; G&A expenses were $1.1M vs $1.0M.
- Chemomab entered a definitive merger agreement with Scipher Medicine on July 7, 2026, an all-stock transaction valuing the combined company at $150M pre-money.
- Chemomab shareholders are expected to own ~32% of the combined company; Scipher holders ~68%, prior to a concurrent $30M PIPE.
- Chemomab shareholders will receive CVRs: $10M upon FDA approval of nebokitug for any indication and $40M if the PSC program advances to Phase 3 or is partnered.
- The combined company expects to trade on Nasdaq under ticker 'SCIP' and focus on a Phase 2 RA trial of nebokitug, with topline results expected H1 2028.
- The company has incurred recurring losses of ~$116M, negative operating cash flow of $3.7M in H1 2026, and no approved products, raising substantial doubt about its ability to continue as a going concern.
- Cash runway is expected to fund operations only through Q1 2027.
- The company issued 34,760 ADSs under the LifeSci ATM during H1 2026 for net proceeds of ~$68K.
Financial Impact
Cash burn of $1.3M per quarter; cash runway through Q1 2027; merger provides $30M PIPE to extend runway through Phase 2 RA readout in H1 2028
Risk Factors
- Merger may not close due to failure to obtain shareholder approval, SEC review issues, or tax rulings from the Israel Tax Authority.
- The company has a going-concern warning and only ~6 months of cash runway without the merger closing.
- Nebokitug is still in clinical development with no approved products and faces significant regulatory and clinical risk.
- The combined company's stock will trade under a new ticker (SCIP), and current CMMB holders will own only ~32% of the combined entity.
- The CVRs are non-transferable and contingent on future milestones that may never be achieved.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-004193 |
| Exhibit: exhibit_99-2.htm | 0001178913-26-004193 |
| Exhibit: exhibit_99-3.htm | 0001178913-26-004193 |
| Document: zk2635899.htm | 0001178913-26-004193 |
| Document: 0001178913-26-004193-index-headers.html | 0001178913-26-004193 |
| Document: 0001178913-26-004193-index.html | 0001178913-26-004193 |
| Document: 0001178913-26-004193.txt | 0001178913-26-004193 |
Track record
15 reports on CMMB
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +33.01% at T+60 after the Aug 19, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13D Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 10, 20266d ago DEFA14A Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $1.18 Now $1.62 +37.29% settles Feb 1
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 30, 202617d ago DEFM14A Neutral 6/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $1.18 Now $1.62 +37.29% settles Jan 15
- Sep 30, 20266w ago 6-K Neutral 4/10 Entry $1.30 Now $1.62 +24.62% settles Dec 28
- Aug 19, 202612w ago 6-K Neutral 6/10 Viewing Entry $2.09 to $1.40 Now $1.62 −22.49% ▼ −33.01% −31.46% vs SPY
- Aug 19, 202612w ago Press Release Bearish 6/10 Entry $2.09 to $1.40 Now $1.62 +22.49% ▲ +33.01% +31.46% vs SPY
- Jul 8, 202618w ago 6-K Bullish 7/10 Entry $1.97 to $1.19 Now $1.62 −17.77% ▼ −39.59% −41.91% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers